Marvin & Palmer Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Marvin & Palmer Associates’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-12,400	Closed	-$1.94M	–	57
2015 Q3	$1.94M	Sell	12,400 -1,700	-12%	-$310K	2.32%	21
2015 Q2	$2.55M	Sell	14,100 -100	-0.7%	-$17.3K	2.41%	20
2015 Q1	$2.46M	Buy	14,200 +1,422	+11%	+$257K	2.13%	21
2014 Q4	$2.36M	Buy	12,778 +1,923	+18%	+$356K	2.4%	13
2014 Q3	$1.8M	Buy	+10,855	New	+$1.78M	1.83%	21
2013 Q4	–	Sell	-9,700	Closed	-$1.13M	–	77
2013 Q3	$1.13M	Buy	+9,700	New	+$1.06M	0.74%	56

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Marvin & Palmer Associates's ALXN Position: Q4 2015 in Review

Marvin & Palmer Associates sold out of Alexion Pharmaceuticals (ALXN) in Q4 2015, closing a stake of 12,400 shares — an estimated $1.94M sold.

Marvin & Palmer Associates first reported a position in ALXN in Q3 2013 and held it in 6 quarters. The position peaked at $2.55M in Q2 2015. 547 funds tracked by Wall St. Rank hold ALXN as of Q4 2015.

Marvin & Palmer Associates reported no remaining Alexion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Marvin & Palmer Associates sold 12,400 Alexion Pharmaceuticals shares in Q4 2015, an estimated $1.94M.
Marvin & Palmer Associates first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 6 quarters.
Marvin & Palmer Associates's Alexion Pharmaceuticals position peaked at $2.55M in Q2 2015.
547 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2015.

Based on Marvin & Palmer Associates's 13F filing for Q4 2015, filed 11 Feb 2016.